Investors are cheered by the company's latest set of quarterly results, in spite of a deeper net loss.
PALO ALTO, Calif., August 05, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria. Among the 10 abstracts are oral presentations and posters highlighting the use of Guardant360™ to help physicians inform
Guardant Health (GH) delivered earnings and revenue surprises of -80% and 4.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?